Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Study of Ixazomib + Lenalidomide + Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma
jRCT1080223804Phase 4Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Takeda. Primary endpoints: Effectiveness of IRd in real-world practice and Safety and tolerability of IRd in real-world practice. Started Feb 2018; status: completed.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT1080223804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223804.